How to Get Rezdiffra (Resmetirom) in Delaware

What Is Rezdiffra and Why Does It Matter for Delaware Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting MASH, a progressive liver disease formerly called non-alcoholic steatohepatitis. The FDA granted accelerated approval in March 2024 based on surrogate histological endpoints from the MAESTRO-NASH trial.

Before this approval, no pharmacotherapy existed for MASH. Patients in Delaware and elsewhere relied on lifestyle modifications alone, a strategy that produces histological improvement in fewer than 10% of cases with advanced fibrosis [1]. Resmetirom works as a thyroid hormone receptor-beta (THR-β) agonist, selectively activating receptors in the liver to reduce hepatic fat, inflammation, and fibrotic signaling without the cardiac or bone side effects of systemic thyroid hormone. In the MAESTRO-NASH phase 3 trial (N=966), 25.9% of patients on the 80 mg dose and 29.9% on the 100 mg dose achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo [1]. Fibrosis improvement of at least one stage without MASH worsening occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group versus 14.2% for placebo [1].

Delaware has approximately 80,000 adults living with NAFLD/MASLD, and an estimated 15,000 to 20,000 of those have progressed to MASH, according to modeling based on CDC prevalence data. Access in a small state with limited hepatology specialists makes telehealth and pharmacy logistics especially relevant.

Telehealth Prescribing in Delaware

Delaware law permits licensed prescribers to evaluate, diagnose, and prescribe controlled and non-controlled medications via telehealth, including resmetirom. A patient does not need an in-person visit before receiving a Rezdiffra prescription if the telehealth encounter meets the standard of care.

Several national telehealth platforms now include hepatology or gastroenterology specialists who can prescribe resmetirom. HealthRX connects Delaware residents with board-certified providers experienced in MASH management. The typical telehealth workflow involves a medical intake form, review of existing labs and imaging, a synchronous video consultation, and electronic prescribing to a pharmacy of the patient's choice.

Delaware's Board of Medical Licensure requires that telehealth prescribers hold an active Delaware medical license or a recognized interstate compact license. Nurse practitioners in Delaware have full practice authority under state law, meaning they can independently evaluate and prescribe resmetirom without physician oversight. Physician assistants may also prescribe under their collaborative agreement.

One practical advantage for Delaware patients: the state's small geography means that when a telehealth provider orders labs, the patient is rarely more than 30 minutes from a Quest Diagnostics or Labcorp draw site. Christiana Care and Bayhealth both accept outside lab orders electronically, which simplifies the pre-prescription workup.

Required Labs Before Starting Rezdiffra

Prescribers must confirm the MASH diagnosis and assess fibrosis stage before writing a resmetirom prescription. The FDA prescribing information specifies the drug for patients with MASH and moderate-to-advanced hepatic fibrosis (F2-F3).

Baseline labs typically include a comprehensive metabolic panel with hepatic function (ALT, AST, ALP, bilirubin, albumin), a complete blood count, thyroid function tests (TSH and free T4), lipid panel, and HbA1c. The FIB-4 index, calculated from age, platelet count, ALT, and AST, serves as a non-invasive fibrosis screening tool. A FIB-4 score above 1.3 warrants further evaluation, and scores above 2.67 strongly suggest advanced fibrosis [2].

For fibrosis staging confirmation, providers use either vibration-controlled transient elastography (FibroScan) or MR elastography. FibroScan is available at Christiana Care's liver clinic in Newark and at select gastroenterology practices in Wilmington and Dover. A liver stiffness measurement between 8.0 and 13.9 kPa generally corresponds to F2-F3 fibrosis [3]. Liver biopsy remains the gold standard but is not required for every patient. The AASLD practice guidance supports non-invasive testing as sufficient for treatment decisions in most clinical scenarios.

Thyroid monitoring deserves special attention. Resmetirom's THR-β selectivity minimizes systemic thyroid effects, but the FDA label recommends checking TSH before initiation and periodically during treatment. In MAESTRO-NASH, clinically significant TSH suppression was rare (occurring in <1% of patients), but mild TSH decreases were observed more frequently than with placebo [1].

Delaware Medicaid and Insurance Coverage

Delaware Medicaid covers Rezdiffra with prior authorization. The PA process requires documentation of a confirmed MASH diagnosis, evidence of F2-F3 fibrosis (via elastography, biomarkers, or biopsy), and failure of or contraindication to lifestyle intervention alone.

Commercial insurers in Delaware vary widely. As of early 2026, Highmark Blue Cross Blue Shield of Delaware and Aetna have published coverage policies requiring prior authorization with clinical documentation. The typical PA packet includes the prescriber's clinical notes, lab results showing elevated ALT/AST, FIB-4 score or elastography report, and a statement confirming the fibrosis stage. Some insurers also require documentation that the patient has attempted at least 6 months of structured lifestyle modification.

The manufacturer's co-pay assistance program may reduce out-of-pocket costs for commercially insured patients. Madrigal Pharmaceuticals offers a patient support program that helps with benefits verification and appeals. For patients without coverage, the wholesale acquisition cost of Rezdiffra is approximately $47,400 per year, though actual pharmacy pricing varies.

Appeals are common. A 2025 analysis published in Hepatology Communications found that initial PA denial rates for novel MASH therapeutics exceeded 30% across commercial plans, but that 60% to 70% of denials were overturned on first appeal when supported by hepatology specialist documentation and fibrosis staging evidence [4].

Prior Authorization Documentation: What Delaware Providers Need

The PA submission for Rezdiffra in Delaware generally requires six components. Miss one and the request stalls.

First, the prescriber must submit a completed PA request form specific to the patient's insurer. Second, clinical notes from the evaluation visit (in-person or telehealth) must document the MASH diagnosis, including relevant history such as metabolic syndrome components, elevated liver enzymes, and imaging findings. Third, the fibrosis staging report is required. This can be a FibroScan printout, MR elastography report, or liver biopsy pathology result showing F2 or F3 fibrosis. Fourth, baseline lab results (hepatic panel, CBC, TSH) must be dated within 90 days of the request. Fifth, the prescriber should include a brief clinical rationale explaining why resmetirom is medically necessary, often referencing the lack of alternative FDA-approved MASH therapies. Sixth, some plans require a letter of medical necessity signed by the prescribing clinician.

Turnaround time for PA decisions in Delaware ranges from 48 hours to 14 business days depending on the insurer. Urgent or expedited reviews can be requested if the patient's clinical status warrants faster action, though MASH rarely qualifies as urgent under most payer definitions.

Pharmacy Access and 503A Compounding in Delaware

Rezdiffra is dispensed as a manufactured tablet (80 mg and 100 mg) through specialty pharmacies. Most prescriptions are routed to national specialty pharmacy networks such as Accredo, AllianceRx Walgreens, or Optum Specialty Pharmacy. These pharmacies ship directly to the patient's address in Delaware, typically with cold-chain or controlled-environment packaging as needed.

Delaware also permits dispensing through licensed 503A compounding pharmacies. Under FDA guidance, 503A pharmacies compound medications based on individual patient prescriptions, while 503B outsourcing facilities compound without patient-specific prescriptions. For resmetirom specifically, 503A pharmacies in Delaware may compound formulations if a prescriber determines that the commercially available dosage form does not meet a patient's clinical needs (for example, a patient who cannot swallow tablets and requires a liquid formulation).

It is worth noting that most patients will receive the commercially manufactured Rezdiffra tablet rather than a compounded version. Compounding is the exception rather than the rule for this drug, reserved for patients with specific formulation needs.

Local retail pharmacies in Delaware (CVS, Walgreens, Rite Aid) generally do not stock Rezdiffra. The drug's specialty designation means it flows through specialty pharmacy channels. Patients should expect a coordination call from the specialty pharmacy within 2 to 5 business days of prescription submission, during which the pharmacy confirms insurance coverage, arranges delivery logistics, and provides medication counseling.

Who Can Prescribe Rezdiffra in Delaware

Three categories of clinicians hold prescriptive authority for resmetirom in Delaware. Physicians (MDs and DOs) with active Delaware licensure can prescribe without restriction. Nurse practitioners in Delaware operate under full practice authority as codified in Delaware Code Title 24, Chapter 19, meaning they can independently diagnose MASH, order staging workups, and prescribe resmetirom. Physician assistants may prescribe under their supervising physician's delegation agreement, which must explicitly include the authority to prescribe legend drugs.

In practice, most resmetirom prescriptions originate from hepatologists, gastroenterologists, or endocrinologists. Primary care physicians and nurse practitioners are increasingly comfortable initiating the workup, particularly when supported by non-invasive fibrosis tools like FIB-4 and FibroScan. A referral to hepatology is not strictly required but may strengthen PA submissions, as some insurers weigh specialist involvement in their coverage determinations.

Delaware has a limited number of board-certified hepatologists. The American Association for the Study of Liver Diseases has noted the nationwide hepatologist shortage and endorsed task-sharing models where primary care and advanced practice providers manage early-to-moderate MASH with specialist consultation available for complex cases [5].

What to Expect: Timeline from Evaluation to First Dose

The process from initial evaluation to receiving Rezdiffra typically spans two to four weeks in Delaware. Here is a realistic breakdown.

Week one: the patient completes a telehealth or in-person evaluation. The provider reviews existing records, orders any outstanding labs, and discusses the treatment plan. If labs are already available and fibrosis staging is documented, the prescription can be submitted on the same day.

Week one to two: lab results return (typically 1 to 3 business days for standard panels; FibroScan appointments may require scheduling). The provider confirms eligibility, selects the appropriate dose (80 mg for patients weighing <100 kg, 100 mg for those ≥100 kg per the FDA label), and submits the prescription along with the PA packet.

Week two to three: the insurer processes the PA request. Approval triggers pharmacy processing. Denial triggers an appeal, which adds 7 to 14 business days.

Week three to four: the specialty pharmacy contacts the patient, confirms shipping details, and dispatches the medication. Most patients receive their first shipment within 3 to 5 business days of pharmacy processing.

Patients transferring an existing Rezdiffra prescription from another state to a Delaware pharmacy face minimal barriers. The prescriber can send a new electronic prescription to any Delaware-licensed specialty pharmacy, or the patient can request a prescription transfer through their pharmacy network. Interstate prescription transfers for non-controlled legend drugs are straightforward under Delaware pharmacy regulations.

Dosing, Monitoring, and Follow-Up

Resmetirom is taken once daily with food. The two available strengths, 80 mg and 100 mg, are assigned based on body weight. Patients should take the tablet at approximately the same time each day. No dose titration is required.

Follow-up monitoring includes hepatic function tests (ALT, AST) at 3-month intervals for the first year, thyroid function tests at 3 and 6 months, and repeat fibrosis assessment at 12 months. The AASLD guidance recommends using the same non-invasive modality (FibroScan or MR elastography) for longitudinal comparison.

Common adverse effects observed in MAESTRO-NASH included diarrhea (26.8% vs. 18.2% placebo) and nausea (18.5% vs. 14.5% placebo) [1]. Most gastrointestinal symptoms were mild to moderate and resolved within the first 4 to 8 weeks. Serious adverse events occurred at similar rates in the resmetirom and placebo groups.

Patients on levothyroxine or other thyroid medications should have TSH monitored more frequently, as resmetirom's hepatic THR-β activation may alter thyroid hormone metabolism. The FDA label advises against use in patients with decompensated cirrhosis (Child-Pugh B or C).

The MAESTRO-NASH Trial: Evidence Behind the Approval

The MAESTRO-NASH trial was a phase 3, randomized, double-blind, placebo-controlled study enrolling 966 adults with biopsy-confirmed MASH and fibrosis stages F1B through F3 at 200 sites globally. The two co-primary endpoints at 52 weeks were MASH resolution without fibrosis worsening and fibrosis improvement by at least one stage without MASH worsening.

Both endpoints were met with statistical significance. For MASH resolution: 25.9% (80 mg) and 29.9% (100 mg) versus 9.7% placebo (P<0.001 for both comparisons). For fibrosis improvement: 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% placebo (P<0.01 and P<0.001, respectively) [1].

Secondary endpoints showed meaningful reductions in hepatic fat content measured by MRI-PDFF: a relative reduction of approximately 45% at 52 weeks versus 10% with placebo. LDL cholesterol dropped by 13% to 16%, and liver enzyme normalization rates were significantly higher in the treatment groups [1].

The trial's accelerated approval pathway means a confirmatory phase 3b study (MAESTRO-NASH-OUTCOMES) is ongoing, with results expected in 2028. This trial will assess hard clinical outcomes including progression to cirrhosis, liver transplantation, and liver-related mortality.